Document is current

Article History

Received: 27 January 2025

Accepted: 17 April 2025

First Online: 9 May 2025

Declarations

:

: This study does not report on experiments on humans and/or the use of human tissue samples. It was conducted in accordance with the Declaration of Helsinki, Health Research Authority (HRA) in the United Kingdom and Good Clinical Practice (GCP) guidelines. Institutional review board (IRB) approval was obtained from London North West University Healthcare NHS Trust in the United Kingdom (evaluation reference number SE21/003) who waived the need for ethical approval and patient consent as anonymised retrospective EHR was used.

: We did not use any personally identifiable patient data and therefore patient consent was not required for publication.

: C.W. has received sponsor fees with Dr Falk Pharma. P.B. has no conflicts of interest. N.K. has received speaker fees from Abbvie, Janssen and Takeda in addition to sponsor fees from Tillots, Takeda and Janssen. R.M has received speaker fees from Abbvie. L.Y. has received lecture, advisory board and personal fees from Abbvie, Janssen and Takeda. L.D. has received speaker fees from Dr Falk Pharma and Abbvie. K.Y. has received sponsor and speaker fees from Abbvie. C.R. has no conflicts of interest. N.A. has received grant support from Janssen in addition to lecture, advisory and personal fees from Takeda, Janssen, Galapagos and Pfizer.